Johns Hopkins Diabetes Guide
PCSK9 Inhibitors
INDICATIONS
FDA
FDA
To be used as an adjunct to diet and maximally tolerated statin therapy in:
- Adult patients with heterozygous familial hypercholesterolemia
- Adult patients with homozygous familial hypercholesterolemia
- Patients with clinical atherosclerotic cardiovascular disease who require additional LDL lowering
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: October 4, 2020
Citation
Patel, Nisha K, et al. "PCSK9 Inhibitors." Johns Hopkins Diabetes Guide, 2020. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547208/all/PCSK9_Inhibitors.
Patel NK, Khan S, Crowder A. PCSK9 Inhibitors. Johns Hopkins Diabetes Guide. 2020. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547208/all/PCSK9_Inhibitors. Accessed September 28, 2023.
Patel, N. K., Khan, S., & Crowder, A. (2020). PCSK9 Inhibitors. In Johns Hopkins Diabetes Guide https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547208/all/PCSK9_Inhibitors
Patel NK, Khan S, Crowder A. PCSK9 Inhibitors [Internet]. In: Johns Hopkins Diabetes Guide. ; 2020. [cited 2023 September 28]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547208/all/PCSK9_Inhibitors.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - PCSK9 Inhibitors
ID - 547208
A1 - Patel,Nisha,PharmD, MBA, BCPS
AU - Khan,Saira,M.D.
AU - Crowder,Alona,Pharm.D.
Y1 - 2020/10/04/
BT - Johns Hopkins Diabetes Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547208/all/PCSK9_Inhibitors
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
